PeDRA

Pediatric Dermatology Research Alliance

Archive

Webinar: Understanding EB Biology and Recent Advances in EB Clinical Research and Q&A Session

By

Hosted on January 11, 2021. PeDRA President-Elect Anna Bruckner, MD, MSCS gave a presentation on basic biology underlying EB and recent advances in EB clinical research. Webinar sponsored by Amryt Research Ltd.

Understanding EB Biology and Recent Advances in EB Clinical Research and Q&A Session, Sponsored by Amryt Research Ltd.
Monday, January 11, 2021, 5:30 PM PST / 8:30 PM EST

Speaker: Anna Bruckner, MD, MSCS

WATCH NOW

Speaker

Anna Bruckner, MD, MSCS

Dr. Bruckner is Associate Professor of Dermatology and Pediatrics and at the University of Colorado School of Medicine and Director of Pediatric Dermatology at Children’s Hospital Colorado. She attended Northwestern University as part of the Honors Program in Medical Education, earning her MD in 1997. She completed residencies pediatrics and dermatology at the University of Colorado followed by a fellowship in pediatric dermatology at the University of California San Francisco. She maintains board-certification in dermatology and pediatric dermatology.

Dr. Bruckner is passionate about improving outcomes and quality of life for children with skin disorders through patient care, research, education and advocacy. Her academic interests include genetic skin disorders – particularly epidermolysis bullosa (EB), vascular anomalies, atopic dermatitis, and complex patients. She is the principal investigator for the Epidermolysis Bullosa Clinical Research Consortium, a network of North American EB care centers collaborating in clinic research aimed at improving the care and outcomes for patients with EB.

Dr. Bruckner is a founding member of the Pediatric Dermatology Research Alliance (PeDRA) and served on PeDRA’s Executive Committee until 2016. She is now the 2022 President-Elect.

    PeDRA will evaluate content for suitability for its audience but is not responsible for the creation of content, selection of speakers, or delivery of presentations. Please email us at info@pedraresearch.org with any questions or concerns. This webinar is being hosted by PeDRA and sponsored by Amryt Research Ltd.
    Date of preparation: December 2020. VV-MED-00552

    Webinar: EB-101 Clinical Development Update and Q&A Session

    By

    Hosted on November 12, 2020 in partnership with Abeona Therapeutics, this webinar presented cutting edge clinical development updates towards the treatment of epidermolysis bullosa. The webinar featured presentations from Jean Tang, MD, PhD (Professor of Dermatology, Stanford University Medical Center and Principal Investigator, EB-101 pivotal Phase 3 VIITAL study) and Michael Amoroso (Chief Commercial Officer, Abeona) and moderated discussion.

    EB-101 Clinical Development Update and Q&A Session, sponsored by Abeona Therapeutics
    Thursday, November 12, 2020 8:00 AM PST / 11:00 AM EST

    Speakers: Jean Tang, MD, PhD and Michael Amoroso

    watch now

    Speakers

    Jean Tang, MD, PhD

    Professor of Dermatology, Stanford University Medical Center AND Principal Investigator, EB-101 pivotal Phase 3 VIITAL study

    Dr. Tang’s research focuses on genetic skin diseases such as Basal Cell Nevus Syndrome and Epidermolysis Bullosa. She studies new ways to treat and prevent NSMC and melanoma. Dr. Tang has led or co-led the conduct and completion of 6 investigator initiated clinical trials in BCC and EB. She received her MD/PhD from Stanford (Biophysics), completed her dermatology residency at Stanford, and then went to UCSF for a 3 year post-doc in mouse genetics, while simultaneously pursuing formal coursework in biostatistics, epidemiology, and clinical trial design in the KL2 CTSI program.

      Michael Amoroso, MBA

      Chief Commercial Officer, Abeona

      Michael Amoroso joined Abeona as Senior Vice President and Chief Commercial Officer in July 2020, bringing over 20 years of product commercialization experience in the biotechnology and pharmaceutical industries with a focus on cell and gene therapies, and a proven track record of launching innovative drugs for rare diseases.

      Prior to joining Abeona, Mr. Amoroso held various senior level commercial positions at leading biopharmaceutical companies, including Kite, Eisai Inc., Celgene Corporation (now a subsidiary of Bristol-Myers Squibb Company), and Sanofi. At Kite, he was responsible for the company’s worldwide commercial organization leading the commercialization efforts for the autologous CAR T-cell therapy, YESCARTA®, and the future cell therapy pipeline. Before Kite, Mr. Amoroso was Senior Vice President, Americas for Eisai’s Commercial Oncology Business Group, where he was accountable for teams charged with creating and driving commercial strategy and implementation for the company’s approved products and earlier-stage assets. Previously, Mr. Amoroso worked at Celgene for six years in several commercial roles before serving as the organization’s Commercial Lead for CAR T-cell therapy programs. In this capacity, he helped Celgene develop an organizational model to commercialize cell therapies including specialized manufacturing and customer services for patients with lymphoma and myeloma. Before joining Celgene, Mr. Amoroso held various marketing and sales leadership positions over his 10-plus year tenure at Sanofi.

      Mr. Amoroso earned his M.B.A. in Management from the Stern School of Business, New York University, and his B.A. in Biological Sciences, summa cum laude, from Rider University.

        This webinar is being hosted by PeDRA and sponsored by Abeona Therapeutics. PeDRA will evaluate content for suitability for its audience but is not responsible for the creation of content, selection of speakers, or delivery of presentations. Please email us at info@pedraresearch.org with any questions or concerns.

        Series: Emerging Therapies for Moderate-to-Severe Atopic Dermatitis in Children

        By

        Moderate-to-severe atopic dermatitis is associated with negative impacts on quality of life and health outcomes in all age groups, with the impact on children and families being uniquely severe. However, the rapid pace of drug development and uncertainty around novel medications may impact the shared decision-making process and lead to suboptimal treatment of many children. Thus, educating pediatric dermatologists and allergists is critical to positively affect treatment decisions and improve long-term outcomes. In addition, engaging experts in pediatric dermatology and allergy to consider what are the most important research issues in atopic dermatitis is important to direct future efforts. To address this need and help fill the gap left by canceled conferences in 2020, PeDRA is conducting a six-part educational series Emerging Therapies for Moderate-to-Severe Atopic Dermatitis in Children.      

        Being hosted by distinguished faculty in pediatric dermatology and allergy/immunology, this non-CME program will include a total of six parts, including two webinars, two podcasts, and two virtual meetings/townhalls. 

        Part 1: PEDIATRIC ATOPIC DERMATITIS – New and Emerging Systemic Therapies: An Overview
        RECORDED LIVE: Tuesday, October 6, 2020, 5:15 – 6:15PM PDT / 8:15 – 9:15PM EDT

        Chair: Lawrence Eichenfield, MD
        Speakers: Megha Tollefson, MD and Bob Geng, MD
        Panel: Wynnis Tom, MD and Dawn Davis, MD

        View Full Agenda

        5:15 – 5:20 – Introduction
        5:20 – 5:37 – Biologics – Overview and translation to practice
        5:37 – 5:49 – JAK-inhibitors
        5:49 – 6:01 – Mechanisms of action and allergy perspectives
        6:01 – 6:15 – Moderated discussion with audience

        Watch NOW

        Part 2: PEDIATRIC ATOPIC DERMATITIS – Algorithms of the Future
        RECORDED LIVE: Tuesday, October 13, 2020, 5:15 – 6:15PM PDT / 8:15 – 9:15PM EDT

        Chair: Lawrence Eichenfield, MD
        Speakers: Dawn Davis, MD and Wynnis Tom, MD
        Panel: Megha Tollefson, MD and Bob Geng, MD

        View Full Agenda

        5:15 – 5:20 – Introduction
        5:20 – 5:32 – New topicals for moderate to severe disease
        5:32 – 5:42 – New and traditional systemics: where do they fit?
        5:42 – 6:00 – Considerations when selecting appropriate therapy for the appropriate patient
        6:00 – 6:15 – Interactive discussion on “hot” research issues in moderate to severe atopic dermatitis for pediatric dermatologists and allergists

        Watch now

        Part 3: Systemic Therapy for Moderate-to-Severe AD in Children: Where are We?
        AVAILABLE NOW

        Host: Lawrence Eichenfield, MD
        Guests: Dawn Davis, MD, Bob Geng, MD, and Wynnis Tom, MD
        Guests

        LISTEN NOW:

        Subscribe to PeDRA Podcasts

        Part 4: Systemic Therapy for Moderate-to-Severe AD in Children: Where are We?
        Tuesday, December 8, 2020 5:15 – 6:15PM PST / 8:15 – 9:15PM EST

        Host: Lawrence Eichenfield, MD
        Guests: Dawn Davis, MD, Bob Geng, MD, and Wynnis Tom, MD
        Special Guests: Emma Guttman-Yassky, MD, PhD and Eric Simpson, MD

        LISTEN NOW:

        Subscribe to PeDRA Podcasts

        Part 5: Patient Perspectives on Therapies for Moderate-to-Severe AD in Children
        AVAILABLE NOW

        Host: Dawn Davis, MD
        Special Guests: Charlene Miciano and Sarah Pry

        LISTEN NOW:

        Subscribe to PeDRA Podcasts

        Part 6: Patient Perspectives on Therapies for Moderate-to-Severe AD in Children
        Tuesday, January 5, 2021, 5:15 – 6:15PM PST / 8:15 – 9:15PM EST

        An open discussion with faculty and patient advocates in follow-up to the second podcast. Bring your questions or just listen in.

        Host: Dawn Davis, MD
        Guests: Lawrence Eichenfield, MD, Bob Geng, MD, and Wynnis Tom, MD
        Special Guests: Korey Capozza, MPH from Global Parents for Eczema Research and Wendy Smith Begolka, MBS from the National Eczema Association

        LISTEN NOW:

        Subscribe to PeDRA Podcast

        FACULTY

        Lawrence Eichenfield, MD

        Chair

        Professor of Dermatology and Pediatrics
        Chief, Pediatric and Adolescent Dermatology
        Vice Chair, Department of Dermatology
        University of California, San Diego and Rady Children’s Hospital, San Diego

          Bob Geng, MD

          Assistant Professor of Medicine and Pediatrics
          Divisions of Adult and Pediatric Allergy & Immunology
          Co-Director of the Allergy Asthma Foundation of America sponsored UCSD Pediatric Severe Asthma Program
          Allergy/Immunology Director of the Multidisciplinary Atopic Dermatitis Program
          University of California, San Diego and Rady Children’s Hospital, San Diego

            Dawn Davis, MD

            Professor of Dermatology and Pediatrics
            Division Chair, Clinical Dermatology
            Director, Section of Pediatric Dermatology
            Mayo Clinic Rochester

              Megha Tollefson, MD

              Associate Professor of Dermatology and Pediatrics
              Consultant, Dermatology
              Consultant, Pediatric and Adolescent Medicine
              Mayo Clinic Rochester

                Wynnis Tom, MD

                Clinical Professor of Dermatology and Pediatrics
                Fellowship Program Director
                Pediatric & Adolescent Dermatology
                University of California, San Diego and Rady Children’s Hospital, San Diego

                  SPECIAL GUESTS

                  Emma Guttman-Yassky, MD, PhD

                  Vice Chair for Research
                  Incoming System Chair of the Kimberly and Eric J. Waldman Department of Dermatology
                  Icahn School of Medicine at Mount Sinai

                    Charlene Miciano

                    Charlene is a college student from San Diego majoring in bioinformatics. Her experience with eczema growing up influenced her to become an ambassador for the National Eczema Association. When she’s not coding, she enjoys music in many forms, whether it be playing piano or ukulele, doing karaoke, or going to concerts.

                      Korey Capozza, MPH

                      Korey is the founder and executive director of Global Parents for Eczema Research and the mother of a child with moderate to severe eczema. Her professional background is in public health, collaborative leadership, and patient-centered research.

                        Eric Simpson, MD

                        Professor of Dermatology
                        Oregon Health and Science University

                          Sarah Pry

                          Sarah is a mother of 2, Aiden age 12 and Bayle age 8. Aiden has severe eczema. Sarah works full time as an insurance agent in TN and in what spare time she has as a mom, she plays with her kids. She also loves to advocate and learn from the experts by volunteering or helping anyway that she can.

                            Wendy Smith Begolka, MBS

                            Ms. Smith Begolka is the VP for Scientific and Clinical Affairs for the National Eczema Association (NEA) where she guides the evolution and growth of NEA’s patient-centric research and clinical care efforts across the organization and with diverse stakeholders. Prior to joining NEA in 2018, she conducted biomedical laboratory research investigating immunological pathways of autoimmune disease at Northwestern University, and for over a decade, led the development of American Academy of Dermatology clinical guidelines and the application of science to the intersecting areas of quality, education, and advocacy. Her 25+ year scientific career has focused on advancing research, the use of scientific discovery and findings to support improved therapeutic options and clinical care, and the translation of research data for educational, quality, advocacy, and policy initiatives.

                              Special thanks to Pfizer Inc. for their support of this independent medical education program.  PeDRA is solely responsible for all program content and the selection of all presenters, authors, moderators, and faculty.

                              Town Hall: Impacts of COVID-19 on Children with Dermatological Disease

                              By

                              In collaboration with PeDRA, GlobalSkin hosted a virtual townhall on June 30, 2020 with Dr. Kelly Cordoro and Dr. Amy Paller to discuss the impact of COVID-19 on children and action being taken by the pediatric dermatology researchers.

                              GlobalSkin, also known as the International Alliance for Dermatology Patient Organizations (IADPO), is a nonprofit organization supporting more than 160 patient associations across more than 50 countries. They seek to improve the lives of patients with all skin disease through advocacy, education, networking, and research. To learn more, visit the GlobalSkin website.

                              Webinar: From the NICU to Eczema and the Value of Research Funding

                              By

                              Tune in to hear Jennifer Schoch, MD from University of Florida discuss her research in the microbiome and eczema, and learn about the value of PeDRA funding.

                              Jennifer Schoch, MD is Pediatric Dermatologist and Assistant Professor of Dermatology at the University of Florida. She is the recipient of a PeDRA Pilot Grant (2018), SPD/PeDRA Weston Career Development award (2019-20), PeDRA Shark Tank Award (2020-21) and an NIH KL2 Award (2020-22).

                              Webinar: Hamartomas and midline anomalies in association with infantile hemangiomas, PHACE, and LUMBAR syndromes

                              By

                              Olivia Davies, MD Candidate and PeDRA Fellow discusses the findings of a recent publication – Hamartomas and midline anomalies in association with infantile hemangiomas, PHACE, and LUMBAR syndromes.

                              Olivia Davies is a third year medical student at the Medical College of Wisconsin. She is currently the ’20-’21 PeDRA Fellow. Upon graduation from medical school, Olivia hopes to pursue a career in dermatology.

                              Podcast: A Roadmap for Navigating the New Eczema Treatment Landscape with Dr. Eric Simpson

                              By

                              Through a special partnership with Global Parents for Eczema Research (GPER), PeDRA co-hosted a podcast interview with Dr. Eric Simpson from OHSU on June 5, 2020.  The podcast features a roadmap of new and emerging eczema treatments and Q&A with a small group of parents and early career PeDRA investigators.  Listen and share the 25-minute podcast, also available for download on these platforms:

                              Picture

                              Picture
                              Picture

                              Webinar: Clinical and Histologic Presentation of Pediatric Reactive Granulomatous Dermatitis

                              By

                              Lisa Arkin, MD presents the findings of a recent PeDRA study: Clinical and Histologic Presentation of Pediatric Reactive Granulomatous Dermatitis.

                              Lisa Arkin, MD is the Director of Pediatric Dermatology and Assistant Professor of Dermatology at the University of Wisconsin, Madison. She has been a member of PeDRA since it’s inception and has served on several committees. She is the principal investigator for several PeDRA studies and was recently awarded a PeDRA Research grant to support her efforts in working towards a precision-based treatment for facial port wine birthmarks. She is currently the Chair of the Early Investigators Committee and oversees the annual EI Forum at the PeDRA Conference and PeDRA Research Mentorship Program.